Variant:
rs1065852 at chr22:42526694 in CYP2D6 (VIP)

Alleles (on + chromosomal strand)
G > A
Amino Acid Translation
Pro34Ser
Alternate Names:
CYP2D6:100C>T, c.100C>T, g.21917263G>A, g.24825C>T, g.40856638G>A, g.5190C>T, p.Pro34Ser, part of CYP2D6*4 and CYP2D6*10
Haplotypes
This variant is used to determine: CYP2D6*10

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 2 annotations for this variant. Register or sign in to see them.

VIP Variant in CYP2D6

CYP2D6 100C>T (also seen as 188C>T in the literature) is part of both the non-functional CYP2D6*4 haplotype and the reduced function CYP2D6*10 haplotype. Since CYP2D6 100C>T is present in both a non-functional and a reduced function haplotype, it is not likely to be the causative SNP for the lack of function observed with CYP2D6*4. According to Gaedigk et al [Article:10634130], the presence of CYP2D6 100C>T (188C>T by their nomenclature), and the absence of CYP2D6 1846G>A (1934G>A) is diagnostic of CYP2D6*10.

In vitro studies in both COS-1 [Article:2211621]and V79 [Article:12386125] cells have shown that cells transfected with CYP2D6 100C>T alone exhibit reduced function, suggesting that this mutation contributes to the reduced function of the CYP2D6*10 allele. Association studies have examined the role of this variant in contributing to generalized tonic clonic seizures (GTCS) seen in epilepsy (no association found) [Article:16835697] and tardive dyskinesia in Chinese Schizophrenic patients (weakly positive) [Article:16490169].

Note: The CYP2D6 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

Key Publications:
Drugs / Other Molecules
Diseases Cystic Fibrosis Depression Hypertension Neoplasms Pain Parkinson Disease Schizophrenia
Phenotype Datasets Hot flashes in tamoxifen patients
Lipid measurements in tamoxifen study
Lipid measurements in tamoxifen study - set 2
Meperidine N-demethylation by human CYP450 isoforms
Metabolism of yohimbine by human CYP450 isoforms
Pharmacokinetics of Tamoxifen at 4 months
Thyroid binding globulin in tamoxifen patients

Appendix

CYP2D6: 100C>T

Genomic Variant & GenBank ID: C1719T on M33388
mRNA Variant & GenBank ID: C100T on X08006
Protein Variant & GenBank ID: P34S on AAH75024
GoldenPath Position: chr22:40856638 on hg 18
DNA Source Containing
Homozygous Reference
Allele(Coriell Lines):
GM17201
DNA Source Containing
Heterozygous
Reference
Allele(Coriell Lines):
GM17203
DNA Source Containing
Homozygous Minor
Allele(Coriell Lines):
GM17225
Key Haplotypes: CYP2D6*4, CYP2D6*10

Connected Drugs

Connected Drug Classes

Evidence Drug Class
Variant Annotation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
antipsychotics

Connected Diseases

Publications related to rs1065852 at chr22:42526694: 5

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Schroth Werner, et al. [Article:18024866@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta pharmacologica Sinica. 2006. Fu Yan, et al. [Article:16490169@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells. Drug metabolism and disposition: the biological fate of chemicals. 2002. Shiraishi Tomoko, et al. [Article:12386125@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999. Gaedigk A, et al. [Article:10634130@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. The Journal of biological chemistry. 1990. Kagimoto M, et al. [Article:2211621@PubMed]

Cross-References

UCSC Golden Path:
chr22:42526694
dbSNP:
rs1065852
ALFRED:
SI000466Q

Platform Availability

  • Illumina

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.